UK Set to Make T+1 Switch in 2027 in Tandem With Europe
The taskforce spearheading the UK's shift to a faster trading regime is recommending the same transition date as the European Union, teeing up a coordinated move favored by the finance industry.
The UK should switch to a one-day settlement cycle known as T+1 on Oct. 11 2027, according to Andrew Douglas, chair of the government-appointed team advising on the transition. That's the same date that the European Securities and Markets Authority has recommended, though formal political approval is still required in both jurisdictions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Tens of thousands march in Romania demanding LGBTQ equality
BUCHAREST (Reuters) -Tens of thousands of Romanians joined an LGBTQ Pride march in Bucharest on Saturday, demanding civil union partnership legislation and equal rights after a highly-contested presidential election last month buoyed the far right. The European Union state has so far ignored a 2023 ruling by the European Court of Human Rights, which found Romania had failed to enforce the rights of same-sex couples by refusing to recognise their relationships. Socially conservative Romania decriminalised homosexuality in 2001, decades later than other parts of the EU, but still bars marriage and civil partnerships for same-sex couples. "We want legal protection for same-sex couples, an easy legal procedure for transitioning, protection against hate speech and prejudice-based crimes," said Teodora Roseti, president of Romanian LGBTQ rights organisation ACCEPT and Pride's organiser. In Bucharest, marchers danced and carried the rainbow flag 20 years after the first Pride parade was held, carrying banners such as "Love is the worst feeling you could hate", "Equality in love, equality in inheritance. Civil partnership for all". Roughly 30,000 people attended the parade, ACCEPT estimated. The march comes at a fraught moment in Central and Eastern Europe, where far right parties have gained ground. Poles held a similar parade on Saturday. Hours before the Romanian march, a smaller anti-Pride protest took place, with participants demanding an Orthodox Christian nation and waving flags carrying the Celtic cross, a known far-right symbol. In Romania, centrist Bucharest mayor Nicusor Dan ultimately won the presidential election against hard-right opposition leader George Simion, a strong opponent of LGBTQ rights. ACCEPT and LGBTQ rights group Mozaiq warned of a rise in hate speech against the community during the election campaign, and their headquarters were defaced. In neighbouring Hungary, parliament passed legislation earlier this year that de facto bans holding Pride marches.
Yahoo
8 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
